CD8A and herpes zoster: Furthermore, CVE markedly outperformed Shingrix in inducing CD8+ tissue-resident memory T cells (TRMs, CD44+CD62L-CD103+), a population essential for mucosal barrier defense and prevention of herpes zoster reactivation.